GAVISCON

GAVISCON Liquid 500 mg/267 mg/160 mg Susp.z.Einn.

Important notes (mandatory information)

Gaviscon Liquid 500 mg/267 mg/160 mg Suspension for oral use. Active ingredients: sodium alginate, sodium hydrogen carbonate and calcium carbonate. Indications: for the treatment of symptoms of gastroesophageal reflux such as acid regurgitation, heartburn, indigestion (in connection with reflux) e.g. after meals, during pregnancy or in patients with symptoms associated with reflux oesophagitis. Warning: Contains methyl 4-hydroxybenzoate (E 218) and propyl 4-hydroxybenzoate (E 216).

Source: Information from the package leaflet
As of: 11/2022